Skip to main content

Safety and efficacy of individualized target transcranial magnetic stimulation for major depressive disorder based on DLPFC-pgACC functional connectivity: a randomized, sham-controlled clinical trial

In brief

Depression scores fell 64% with targeted stimulation, versus 41% with sham

In this randomized, double-blind trial, 65 adults with major depression were analyzed after individualized magnetic stimulation targeted a brain region linked to the pregenual cingulate. Depression scores fell more by the end of treatment with active stimulation than with sham, which also produced a substantial reduction. The trial supports a short-term benefit, but durability and effectiveness in larger groups remain unknown.

Journal
BMC medicine (Q1)
Published
26 August 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Nian Liu, Yaochi Zhang, Runxin Lv, Yuyu Zhang, Nailong Tang, Junchang Liu, et al.
PMID
43058724
DOI
10.1186/s12916-026-05168-1

Why clinicians should know about it

  • Picked for Psychiatry and Mental Health (paper of the day, 21 November 2026): Randomized sham-controlled trial of individualized TMS for major depression

Abstract

BACKGROUND: Major Depressive Disorder (MDD) has emerged as a major global public health challenge. Recently, Stanford neuromodulation therapy, a paradigm of individualized target-transcranial magnetic stimulation (IT-TMS) focusing on the subgenual anterior cingulate cortex (sgACC), has exhibited significant therapeutic benefits in treating MDD. The pregenual anterior cingulate cortex (pgACC), alongside the sgACC, is also an emotional subregion of the anterior cingulate cortex (ACC). This study aims to explore the safety and efficacy of IT-TMS targeting the pgACC for the treatment of MDD. METHODS: This is a randomized, double-blind, sham-controlled trial involving 68 patients with MDD randomly assigned to an IT-TMS group and a sham group. The IT-TMS group receives individualized intermittent theta-burst stimulation targeted at the region in the left dorsolateral prefrontal cortex (DLPFC) with the strongest negative functional connectivity to the pgACC. The sham group undergoes a well-accepted 90°-reversed sham stimulation procedure. The primary outcome is the percentage change in the 17-item Hamilton Rating Scale for Depression (HAMD-17) score from baseline to the end of treatment. RESULTS: In the final intention-to-treat analysis, 31 participants from the IT-TMS group and 34 from the sham group were included. From baseline to the end of IT-TMS treatment, the mean percentage reduction in HAMD-17 score was 64.3% (95% CI: 55.9-72.7) for the IT-TMS group versus 41.4% (95% CI: 33.9-48.8) for the sham group, yielding a significant treatment effect (P = 0.0001). CONCLUSIONS: This IT-TMS therapy has demonstrated good safety and effectiveness in the treatment of MDD, with the ability to rapidly alleviate related symptoms in patients. TRIAL REGISTRATION: This study was registered on the ClinicalTrials.gov (NCT05577481).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.